ERBB2 and breast carcinoma: Datopotamab deruxtecan, another anti-TROP2 mAb, is being investigated in clinical trial for unresectable or metastatic TNBC as well as HER2+/ HER2− breast cancer cases (NCT05374512; NCT05104866) [64, 65].